Skip to main content
. 2008 Apr;4(2):345–351. doi: 10.2147/tcrm.s1265

Figure 1.

Figure 1

Percentage of patients achieving 75% improvement in Psoriasis Area and Severity Index response at week 12 in the phase II and phase III trials. Because the phase II trial did not have week 16 data (the primary endpoint for the phase III trials), we compared the week 12 PASI 75 for all three clinical trials.